Treatment for osteoporosis using hGRF(1-40)NH.sub.2
US4710382A · kind A · utility
11Cited by
1References
10Claims
0Family size
Inventor
Key dates
| Filing date | Sep 27, 1985 |
| Grant date | Dec 1, 1987 |
| Priority date | — |
| Expiry date | Sep 27, 2005 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of treating osteoporosis, especially postmenopausal osteoporosis, by administering on a periodic but regular basis to a patient growth hormone releasing factor, GRF(1-44)--NH.sub.2, or a biologically active analog thereof, and continuing the administration until bone mass increases and the patient's calcium balance becomes positive and indicates a mineral accumulation in the skeleton.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.